Robarts Clinical Trials Inc. – a global academic clinical research organization with offices in San Diego, California, Amsterdam N.L. and London, Ontario – announced a relocation to the Bell Canada Building in downtown London, effective January 1, 2016.
The new corporate headquarters, located at 100 Dundas Street, will provide capacity for increased customer support, clinical operations, business development and leadership functions across the company and will accommodate Robarts Clinical Trials Inc.’s rapid growth and future expansion plans. Its headquarters is currently located at Western University.
An operationally and financially independent subsidiary of Western, Robarts Clinical Trials Inc. was established in 1986 at the Robarts Research Institute and has been part of the Schulich School of Medicine & Dentistry since 2007.
“The new office will allow increased capabilities in areas that align with our strategic needs. This facility will allow expansion of project teams to support growth and provide dedicated space for customer briefings and other essential activities,” says Brian Feagan, Chief Executive Officer and Scientific Director. “The team is excited about our scientific accomplishments and the growth record. This move is a commitment to continued excellence in clinical research.”
Since 2013, the company’s staff has more than doubled, further necessitating the move. Currently, there are 90 people working in the London head office and this number will continue to grow leading up to the downtown move in 2016. An additional 30 employees are employed at their San Diego, CA and Amsterdam, NL offices.
Robarts Clinical Trials Inc. provides expertise in study design, implementation, and interpretation to public and private sector sponsors and academic investigators. The company is currently working with six of the world’s 10 most well-recognized pharmaceutical companies and to date collaborates internationally with more than 1,200 hospitals and clinics around the world on every continent except Antarctica.
For more information, contact Robarts Clinical Trials Inc. at 519-931-5216 or visit https://www.robartsinc.com
MEDIA CONTACT: Jeff Renaud, Senior Media Relations Officer, 519-661-2111, ext. 85165, firstname.lastname@example.org, @jeffrenaud99
ABOUT ROBARTS CLINICAL TRIALS INC.
Established in 1986 at the Robarts Research Institute, Robarts Clinical Trials Inc., now an operationally and financially independent subsidiary of Western University, has conducted studies across a range of therapeutic areas; however, our focus and expertise lies in the design, development, execution and reporting of studies in Inflammatory Bowel Disease (IBD). We have gained global recognition as a leader for our innovation and specialized expertise in Crohn’s disease (CD) and ulcerative colitis (UC), cluster randomization trials, our publications and the provision of CIMS, an innovative central image management solution. This focus has been intentional to allow us to develop a deep expertise and knowledge within our staff, medical partners and sites and to ensure added consulting value for our customers.
Western delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.